Screening evidence concerns a whole pathway, not just a test. Benefits, false results, overdiagnosis and follow-up all belong in the comparison. Finding more abnormalities is not, by itself, proof that a programme improves people's outcomes.
Identify the proposed pathway
A screening programme starts with an eligible population and a test, then needs a plan for assessment and any subsequent care. The UK National Screening Committee's criteria require consideration of the overall balance of benefits and harms, including false results and overdiagnosis.
In a research report, distinguish an invitation to screening from attendance, a positive result and a confirmed diagnosis. Each has a different denominator. “Twenty per cent positive” is incomplete until the reader knows whether that means all invited people, those attending or those with a valid test.
Count outcomes beyond detection
Imagine a new screening approach that identifies twice as many findings as another approach. That could be useful, but the detection count alone does not show how many people benefited or how many underwent unnecessary further investigation. The answer requires follow-up and a comparison of outcomes that matter to participants.
Look for separate reporting of false positives, false negatives, additional procedures and uncertain findings. Overdiagnosis is a distinct concern: detecting something that would not have caused harm during the person?s lifetime. Do not collapse every harm into the single phrase “test accuracy”.
Read the time frame and comparison
Earlier detection changes the date from which survival after diagnosis is counted. A longer period measured from diagnosis therefore needs careful interpretation; it is not automatically evidence of a later death. Identify whether the study compares relevant outcomes from a consistent starting point, such as allocation or invitation.
Retain the population, follow-up duration and comparison pathway. Evidence in one risk group does not automatically justify the same programme for everyone, and a UK policy source does not establish eligibility in another country.
Finish by recording what the study demonstrates about the complete pathway and what remains unknown. This is a guide to evaluating evidence, not advice to accept or decline a personal screening invitation. The prevention research guide explains how outcome choice, absolute effects and uncertainty help make such reports easier to assess.
Screening evidence concerns a whole pathway, not just a test. Benefits, false results, overdiagnosis and follow-up all belong in the comparison. Finding more abnormalities is not, by itself, proof that a programme improves people's outcomes.
Identify the proposed pathway
A screening programme starts with an eligible population and a test, then needs a plan for assessment and any subsequent care. The UK National Screening Committee's criteria require consideration of the overall balance of benefits and harms, including false results and overdiagnosis.
In a research report, distinguish an invitation to screening from attendance, a positive result and a confirmed diagnosis. Each has a different denominator. “Twenty per cent positive” is incomplete until the reader knows whether that means all invited people, those attending or those with a valid test.
Count outcomes beyond detection
Imagine a new screening approach that identifies twice as many findings as another approach. That could be useful, but the detection count alone does not show how many people benefited or how many underwent unnecessary further investigation. The answer requires follow-up and a comparison of outcomes that matter to participants.
Look for separate reporting of false positives, false negatives, additional procedures and uncertain findings. Overdiagnosis is a distinct concern: detecting something that would not have caused harm during the person?s lifetime. Do not collapse every harm into the single phrase “test accuracy”.
Read the time frame and comparison
Earlier detection changes the date from which survival after diagnosis is counted. A longer period measured from diagnosis therefore needs careful interpretation; it is not automatically evidence of a later death. Identify whether the study compares relevant outcomes from a consistent starting point, such as allocation or invitation.
Retain the population, follow-up duration and comparison pathway. Evidence in one risk group does not automatically justify the same programme for everyone, and a UK policy source does not establish eligibility in another country.
Finish by recording what the study demonstrates about the complete pathway and what remains unknown. This is a guide to evaluating evidence, not advice to accept or decline a personal screening invitation. The prevention research guide explains how outcome choice, absolute effects and uncertainty help make such reports easier to assess.
Comments (0)
Want to join the discussion?
Log In to Comment